Loading...
Loading...
India's carboplatin imports from UNITED STATES total $35.7K across 9 shipments from 3 foreign suppliers. AMSTERDAM PHARMA (APTEKA RX.INC) leads with $19.3K in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include ARAGEN LIFE SCIENCES LIMITED. This corridor reflects India's pharmaceutical import demand for carboplatin โ a concentrated sourcing relationship with select suppliers from UNITED STATES.

AMSTERDAM PHARMA (APTEKA RX.INC) is the leading Carboplatin supplier from UNITED STATES to India, with import value of $19.3K across 4 shipments. The top 5 suppliers โ AMSTERDAM PHARMA (APTEKA RX.INC), EUROMED PHARMA US, INC, M/S.RAFF & HALL PHARMACY โ collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) ยท Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | AMSTERDAM PHARMA (APTEKA RX.INC) | $19.3K | 4 | 54.2% |
| 2 | EUROMED PHARMA US, INC | $13.4K | 1 | 37.7% |
| 3 | M/S.RAFF & HALL PHARMACY | $2.9K | 4 | 8.1% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | ARAGEN LIFE SCIENCES LIMITED | $19.3K | 4 | 54.2% |
| 2 | STAR GENOMICS INDIA PRIVATE LIMITED | $13.4K | 1 | 37.7% |
| 3 | HETERO LABS LIMITED |
Visual overview of India's carboplatin UNITED STATES to India import corridor โ top suppliers, destinations, pricing, and trade routes
UNITED STATES โ India trade corridor intelligence
As of April 2026, the United States to India shipping corridor for pharmaceutical imports, including finished Carboplatin formulations, is operating efficiently. Sea freight transit time averages 30 days, while air freight takes approximately 7 days. The majority of shipments are transported by sea (80%), with a smaller portion by air (20%). There are no significant port congestions at major Indian ports such as Jawaharlal Nehru Port (JNPT), Chennai, and Mundra. Freight rates have remained stable, and the exchange rate between the Indian Rupee (INR) and the United States Dollar has been favorable for importers.
The Indian government's Production-Linked Incentive (PLI) scheme aims to boost domestic manufacturing and reduce import dependency. While the PLI scheme has led to increased domestic production of certain pharmaceutical products, the import of specialized formulations containing Carboplatin continues due to the lack of domestic manufacturing capabilities for these specific products.
| $2.9K |
| 4 |
| 8.1% |
The trade relationship between India and the United States is robust, with ongoing discussions to enhance pharmaceutical trade. Negotiations for a Free Trade Agreement (FTA) are underway, focusing on mutual recognition of Good Manufacturing Practices (GMP) and streamlining pharmaceutical trade facilitation. These efforts aim to strengthen bilateral trade and improve access to quality pharmaceutical products.
The landed cost for importing finished Carboplatin formulations from the United States to India includes the following components:
The total landed duty percentage is approximately 28.85%, which is added to the FOB price to determine the final landed cost per unit.
CDSCO registration, import licensing, and quality testing requirements
To import finished pharmaceutical formulations containing Carboplatin into India, the importing company must obtain an Import Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The application process involves submitting Form 40/41, along with necessary documents such as the Free Sale Certificate, Good Manufacturing Practice (GMP) Certificate, and Certificate of Pharmaceutical Product (CoPP). The registration certificate is valid for three years from the date of issue. The timeline for obtaining the Import Registration Certificate is approximately nine months from the date of application.
Imported pharmaceutical formulations containing Carboplatin must undergo quality testing at CDSCO-approved laboratories. The importer is required to submit samples from three consecutive batches for testing, providing adequate samples for reanalysis purposes. The testing includes analysis methods, Certificates of Analysis (CoA) from the exporting country's laboratory, impurity standards, marker compounds, and reference standards. The importer is responsible for the testing fees, which are paid directly to the testing laboratory.
In April 2025, the CDSCO mandated that all imported drugs, including finished formulations containing Carboplatin, require an Import Registration Certificate and an Import License. This regulation aims to prevent the sale of unapproved or illegal medicines in the Indian market. The policy also stipulates that drugs manufactured in Special Economic Zones (SEZs) for export purposes are not permitted for transfer to the Domestic Tariff Area (DTA) for sale and distribution.
Market demand, customs duty structure, and competitive landscape ยท Import duty: 10%
India imports finished Carboplatin formulations to meet the demand for patented and branded products, as well as specific dosage forms not produced domestically. The domestic capacity for manufacturing Carboplatin formulations is limited, leading to a reliance on imports to fulfill market needs. The market size for Carboplatin formulations in India is substantial, with a total export market of $70.9 million across 273 exporters to 138 countries.
Imports of finished pharmaceutical formulations containing Carboplatin under HS Code 30049047 are subject to a Basic Customs Duty (BCD) of 10%. An Integrated Goods and Services Tax (IGST) of 12% is applicable, calculated on the assessable value plus applicable customs duties. A Social Welfare Surcharge (SWS) of 10% on the BCD is levied. There are no preferential duty rates or exemptions available for imports from the United States.
India sources finished Carboplatin formulations from the United States due to the availability of patented formulations, specialized dosage forms, and high-quality products. The United States holds a competitive advantage in the production of these formulations, offering products that may not be manufactured domestically. Other suppliers include China and Germany; however, the United States's share in the Indian market is significant.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports finished Carboplatin formulations from the United States due to the availability of patented formulations, specialized dosage forms, and high-quality products that are not manufactured domestically. The United States's advanced pharmaceutical manufacturing capabilities and adherence to stringent quality standards make it a preferred source for these formulations.
Compared to other origins such as China and Germany, the United States offers superior quality, regulatory compliance, and reliability in the production of finished Carboplatin formulations. While other suppliers may offer lower prices, the United States's products are preferred for their quality and adherence to international standards.
Indian importers face risks such as single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should diversify their supplier base, monitor currency exchange rates, stay updated on regulatory changes, ensure robust quality assurance processes, and maintain contingency plans for shipping disruptions.
Import license checklist, document requirements, quality testing, and compliance
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Carboplatin suppliers from UNITED STATES to India include AMSTERDAM PHARMA (APTEKA RX.INC), EUROMED PHARMA US, INC, M/S.RAFF & HALL PHARMACY. The leading supplier is AMSTERDAM PHARMA (APTEKA RX.INC) with import value of $19.3K USD across 4 shipments. India imported Carboplatin worth $35.7K USD from UNITED STATES in total across 9 shipments.
India imported Carboplatin worth $35.7K USD from UNITED STATES across 9 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Carboplatin sourced from UNITED STATES include ARAGEN LIFE SCIENCES LIMITED, STAR GENOMICS INDIA PRIVATE LIMITED, HETERO LABS LIMITED. The largest buyer is ARAGEN LIFE SCIENCES LIMITED with $19.3K in imports across 4 shipments.
The total value of Carboplatin imports from UNITED STATES to India is $35.7K USD, across 9 shipments and 3 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
9 Verified Shipments
3 suppliers, 3 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists